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ABSTRACT 
Over the recent years, new oral anticoagulant agents 
have been developed and entered the clinical arena, the 
direct or non-vitamin K oral anticoagulants (NOACs). 
Although more expensive, these agents have been proven 
as equivalent or superior to vitamin K antagonists in the 
treatment of non-valvular atrial fibrillation (AF) and 
venous thrombo-embolism with a lower incidence of 
intracerebral hemorrhage. Nevertheless, occurrence of 
major or life-threatening bleeding events is still quite 
possible. Thus, there is a major concern regarding the lack 
of a specific antidote and rapid reversal agent in such 
disastrous situations. Fortunately, the development of 
effective specific NOAC antidotes has recently made great 
advances, which are herein briefly reviewed.  
Key Words: atrial fibrillation; anticoagulation; non-vitamin K 
anticoagulants; dabigatran; rivaroxaban; apixaban; edoxaban; 
intracerebral hemorrhage; bleeding; antidotes; idarucizumab; 
andexanet; aripazine  
Abbreviations 
AF = atrial fibrillation; aPTT = activated partial thromboplastin 
time; dTT = dilute thrombin time; ECT = ecarin clotting time; 
NOACs = non-vitamin K oral anticoagulants; PCC = 
prothrombin complex concentrates; TT = thrombin time; VNAs 
= vitamin K antagonists; VTE = venous thromboembolism  
INTRODUCTION 
Over the recent years, new classes of oral anticoagulant 
agents have been developed and entered into the clinical 
arena, the direct or non-vtamin K oral anticoagulants 
(NOACs). These agents belong to two classes, the direct 
thrombin inhibitor, dabigatran (the -gatrans), and the factor 
Xa inhibitors, such as rivaroxaban, apixan, edoxaban and 
betrixaban (the -xabans).1-4 These agents have been proven 
as equivalent or superior to vitamin K antagonists (VKAs) 
in the treatment of non-valvular atrial fibrillation (AF) and 
venous thromboembolism (VTE),4-6 albeit at an upfront 
increased cost. NOACs confer equivalent or better 
protection from thromboembolic events in these patient 
groups with lessened occurrence of intracerebral 
hemorrhage. However, there still remains, albeit 
decreased, a possibility of such a disastrous cerebral 
bleeding event, while an increased risk of other site or 
major bleeding events has been reported.7 Thus, there is a 
major concern regarding the lack of a specific antidote and 
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rapid reversal agent in case of emergence of a life-
threatening bleeding event. The shorter half-life of these 
agents, and hence a quicker dissipation of their 
anticoagulant effect, is not always entirely reassuring, 
particularly in emergency and menacing situations.  
The risk of hemorrhage-related mortality associated 
with NOACs in patients requiring long-term anti-
coagulation was evaluated by a systematic review and 
meta-analysis of 11 studies (5 on AF and 6 on VTE) 
comprising a total of 100,324 patients receiving 
rivaroxaban (4 studies), dabigatran (3 studies), apixaban (2 
studies) and edoxaban (2 studies).8 NOAC-treated patients 
had a 47% odds reduction compared with VKA (OR 0.53) 
and 64% odds reduction compared with low-molecular 
weight heparin–VKA (OR 0.36) regarding fatal bleeding 
risk. Case fatality due to major bleeding was lower in 
NOAC-treated patients both in AF (OR 0.68) and VTE 
(OR 0.54) patients. AF survivors of major bleeding events 
treated with NOACs had lower mortality compared with 
patients treated with VKAs (OR 0.57). The authors 
concluded that NOACs decrease the mortality risk related 
to major bleeding events, particularly in AF patients. 
Similarly, another meta-analysis of 13 randomized trials 
involving 102,707 patients receiving NOACs for the 
treatment of VTE or prevention of stroke/systemic 
embolism due to AF compared with warfarin or other 
VKAs administered to a target INR 2.0 - 3.0, indicated that 
the case-fatality rate of major bleeding was 7.57% in 
patients taking NOACs vs 11.04% in patients taking 
VKAs.5  When compared with warfarin, NOACs were 
associated with significant reductions in fatal bleeding 
(relative risk-RR, 0.53), cardiovascular mortality (RR, 
0.88) and all-cause mortality (RR, 0.91).  
Nevertheless, the need for a drug-specific antidote with 
rapid reversal properties remains dire despite these 
encouraging results, particularly when urgent surgery with 
a high hemorrhagic risk is needed or in cases of 
intracerebral hemorrhage or serious bleeding in another 
critical organ, or even in cases of accidental overdose, 
where the effect of anticoagulant therapy should be 
promptly reduced. Fortunately, the development of 
effective specific NOAC antidotes has recently made great 
advances,9-13 which are herein briefly reviewed.  
RISK OF MAJOR BLEEDING WITH NOACs 
According with the original studies of each NOAC, the 
risk of major bleeding is not negligible. In the RE-LY trial, 
the rate of major bleeding was 2.71% per year in the group 
receiving 110 mg of dabigatran and 3.11% per year in the 
group receiving 150 mg of dabigatran.14 A higher rate of 
major bleeding with dabigatran 150 mg bid (3.74%) in 
comparison with 110 mg (2.99%) was further confirmed in 
the RELY-ABLE trial (hazard ratio -HR 1.26).15 In the 
ROCKET trial, rate of major bleeding with rivaroxaban 
was 3.6% (similar to warfarin group, 3.4%), rate of 
intracranial hemorrhage was 0.5% (significantly lower 
compared with warfarin, 0.7% per year; HR, 0.67; P = 
0.02).16 However, major gastrointestinal (GI) bleeding was 
more common in the rivaroxaban group (3.2% as 
compared with 2.2% in the warfarin group; P<0.001). A 
subanalysis of the same trial indicated that a significantly 
higher rate of major or non-major clinical GI bleeding was 
encountered in rivaroxaban- vs warfarin-treated patients 
(3.61 events/100 patient-years vs 2.60 events/100 patient-
years; HR: 1.42).17  In the ARISTOTLE trial, major 
bleeding was observed in 2.13% per year in the apixaban 
group, with fatal bleeding (including fatal hemorrhagic 
stroke) occurring in 34 patients.18, 19  In the ADOPT trial, 
among 4495 acutely ill patients with cardiac or respiratory 
failure and/or other medical disorders and risk factors for 
venous thromboembolism, receiving thromboprophylaxis 
with apixaban or subcutaneous enoxaparin, by day 30 
major bleeding had occurred in 0.47% of patients in the 
apixaban group and in 0.19% of patients in the enoxaparin 
group (relative risk, 2.58; P = 0.04).20  In the ENGAGE-
AF TIMI 48 trail, the annualized rate of major bleeding 
was 2.75% with high-dose (60 mg) edoxaban and 1.61% 
with low-dose (30 mg) edoxaban.21 The annualized rate of 
major GI bleeding was higher with high-dose edoxaban 
than with warfarin (1.51% vs. 1.23%), but the rate was 
lowest with low-dose edoxaban (0.82%). In the Explore-
Xa trial, major or clinically relevant non-major bleeding 
was assessed among 508 AF patients randomized to one of 
3 doses (40, 60, or 80 mg once daily) of betrixaban 
(another factor Xa inhibitor mostly excreted unchanged in 
the bile) or unblinded warfarin.22 Over a mean of ~5 
months, the rate of bleeding was lowest on betrixaban 40 
mg (1 event); rates of bleeding with betrixaban 60 or 80 
mg were similar to those of warfarin (5, 5 and 7 events).  
According with a meta-analysis of all 71,683 
participants included in the RE-LY, ROCKET AF, 
ARISTOTLE, and ENGAGE AF-TIMI 48 trials, NOACs 
significantly reduced stroke or systemic embolic events by 
19% compared with warfarin (relative risk - RR 0.81; 
p<0.0001), mainly driven by a reduction in hemorrhagic 
stroke (RR 0.49; p<0.0001), as well as all-cause mortality 
(RR 0.90; p=0.0003) and intracranial hemorrhage (0.48; 
p<0.0001), but had similar major bleeding as with 
warfarin, and increased GI bleeding (RR 1.25; p=0.04).6 
Another meta-analysis of 50 trials including 155,537 
patients, showed that the risk of major bleeding with 
NOACs varies with their indication for use.23  Significantly 
higher major bleeding was noted after hip surgery (odds 
ratio – OR 1.43), in patients with acute coronary syndrome 
(compared against placebo) (OR 2.89), and for medically 
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ill patients (OR 2.79). Less bleeding was observed with 
treatment of acute venous thromboembolism or pulmonary 
embolism (OR 0.63). No significant difference in bleeding 
was found during treatment of AF and for extended 
treatment of venous thromboembolism.   
Although a lower rate of hemorrhagic stroke has been 
consistently reported with use of NOACS,6, 24 admittedly, 
it also appears that the rate of major GI bleeding related to 
the use of at least some NOACs is higher than that reported 
in warfarin users.25, 26 In general, any major bleeding 
during oral anticoagulant treatment is associated with a 
substantially increased subsequent risk of both death and 
of thrombotic events such as ischemic stroke or myocardial 
infarction, especially following intracranial hemorrhage, 
and this risk is similarly elevated regardless of treatment 
with a NOAC or warfarin.27   
Of course, concomitant use of antiplatelet drugs clearly 
increase the risk for major bleeding.28 Other factors 
increasing the risk of major bleeding with NOACs may 
comprise older age, history of smoking, history of prior GI 
bleeding, mild anemia, renal insufficiency, baseline 
diastolic blood pressure >90 mm Hg, history of chronic 
obstructive pulmonary disease, and prior use of aspirin; 
while female gender and diastolic blood pressure <90 mm 
Hg were associated with a decreased risk.29 The effect of 
older age was confirmed by another subanalysis of the 
ROCKET AF trial: although efficacy and safety of 
rivaroxaban relative to warfarin did not differ with age 
(supporting rivaroxaban as an alternative for the elderly), 
elderly patients had higher major bleeding rates than 
younger patients (4.63% vs 2.74%/100 patient-years; 
P<0.0001).30 In another subanalysis, independent clinical 
factors most strongly associated with GI bleeding were 
baseline anemia, history of GI bleeding, and long-term 
aspirin use.17 Although both ischemic stroke and bleeding 
outcomes have been correlated with plasma drug 
(dabigatran) concentrations (trough levels),31  monitoring 
of anticoagulation does not appear to be practical neither 
with this approach, nor with another method 
(thrombelastography) that has been suggested.32   
MANAGING BLEEDING WITH NOACs 
Although NOACs generally seem to confer a lower 
bleeding risk compared to VKAs, management of bleeding 
in patients on NOACs is challenging because there is lack 
of reliable and readily available laboratory tests of 
monitoring the anticoagulant effect of NOACs and 
therapeutic options are few and nonspecific and mostly 
supportive.33  Until now there have been several proposals 
with supportive and other nonspecific measures put forth 
by working groups and societies to manage such situations 
until specific and validated antidotes become available.1, 34  
These proposed actions included postponing or delaying 
the procedure, if at all possible, and monitoring the drug 
concentration for cases in need for urgent surgery, or if the 
dosage was not immediately available, propositions were 
based on laboratory tests, such as prothrombin time (PT) 
and activated partial thromboplastin time (aPTT), or 
measuring the anti-Xa activity; otherwise, supportive 
measures were recommended to be followed, while 
keeping procoagulant drugs at standby to use if and when 
abnormal intra- or post-operative bleeding occurred. In 
cases of bleeding, volume expansion and local hemostatic 
measures, blood transfusion, as needed, and fresh frozen 
plasma and off-label use of a non-specific pro-coagulant 
agent were empirically recommended, such as non-
activated or activated prothrombin complex concentrates 
(PCC), or recombinant human factor VIIa, with its 
attendant shortcomings.35, 36 In the case of dabigatran, 
hemodialysis could also be considered. In patients 
presenting within 2-6 hours of a suspected overdose with 
either dabigatran or apixaban, the use of activated charcoal 
may be a reasonable option.35   
According with data from the ROCKET AF trial, 
during a median follow-up of 1.9 years, 779 (5.5%) 
patients experienced major bleeding at a rate of 3.52 
events/100 patient-years with a similar event rate in each 
arm (n = 395 for rivaroxaban and n = 384 for warfarin).37 
The median number of transfused red packed cells per 
episode was similar in both arms (2 units). Overall, few 
transfusions of whole blood (n = 14), platelets (n = 10), or 
cryoprecipitate (n = 2) were used. Transfusion of fresh 
frozen plasma was significantly less in the rivaroxaban arm 
(n = 45 vs n = 81 units; odds ratio - OR 0.43; P < 0.0001). 
PCC was administered less in the rivaroxaban arm (n = 4 
vs n = 9). Outcomes after major bleeding were similar in 
the 2 groups. The authors concluded that among high-risk 
patients with AF who experienced major bleeding in 
ROCKET AF, the use of fresh frozen plasma and PCC was 
less among those allocated rivaroxaban compared with 
warfarin; however, use of blood transfusion and outcomes 
after bleeding were similar.    
Of course, a most dreaded complication with any 
anticoagulant is intracranial hemorrhage. According to a 
study of 55 patients on NOACs with this complication, the 
30-day mortality rate was 20%.38 Neurosurgical 
procedures were carried out in 37 patients (67%). Renal 
function was significantly lower in non-survivors. Pro-
hemostatic therapy with PCC had no effect. The authors 
concluded that successful neurosurgical management of 
patients with intracranial hemorrhage and NOAC intake 
was feasible, but drastic deterioration was observed in 
some patients, particularly when impaired renal function 
was present, findings which underscore the urgent need of 
improving treatment modalities for these patients.38   
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Several groups have attempted to provide practical 
guidance for the use of NOACs, either in the form of 
advice given in reviews and tabular data or proposing 
checklists, in an attempt to help optimize the risk-benefit 
ratio of NOAC therapy. 1, 3, 4, 39 A European Heart Rhythm 
Association group has listed 15 topics of specific clinical 
scenarios and formulated as practical answers as possible 
based on available evidence.1 A Canadian group proposed 
an evidence-based point-of-care tool—a 1-page NOAC 
ABCD checklist available online: A (adherence), B 
(bleeding), C (creatinine clearance), D (drug interactions), 
E (examination), and F (follow-up).39 The checklist is 
accompanied by quick-reference tables summarizing 
dosing, interactions, and periprocedural management. 
However, when all these safe-keeping proposals have 
failed and one is faced with a threatening situation like 
major bleeding, a contingency plan with effective reversal 
strategies should be in place.33-36 This can only be complete 
with the availability of specific antidotes, which are now 
becoming available,10, 12, 13  as detailed in the next section.   
ANTIDOTES (Table 1) 
 Idarucizumab (Praxbind®), a humanized antibody 
fragment, is a speciﬁc antidote for dabigatran, developed 
by Boehringer Ingelheim.9, 40 This is the first antidote of 
NOAC to receive approval by the FDA (October 16, 2015) 
(http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncem
ents/ucm467300.htm) and the European Medicines Agency 
(EMA) (20/11/2015) (http://www.ema.europa.eu/ema/index. 
jsp?curl=pages/medicines/human/medicines/003986/human_m
ed_001938.jsp&mid=WC0b01ac058001d124). This molecule 
binds to dabigatran with an afﬁnity about 350 times greater 
than thrombin, preventing it from binding to thrombin and 
thus cancelling its anticoagulant effect.41 Idarucizumab is 
specific for dabigatran and does not bind thrombin or its 
substrates, nor does it activate platelets. In animal and 
human studies, idarucizumab did not promote or reduce 
thrombin generation, thus it has no intrinsic anticoagulant 
or procoagulant effects. 
 In a porcine trauma model, idarucizumab reduced 
dabigatran-associated bleeding and mortality.42 It stopped 
bleeding within 15 minutes and was associated with an 
immediate decrease in dabigatran anticoagulant effects. 
There was no evidence of safety concerns associated with 
the administration of idarucizumab.  
In a phase 1 randomized, placebo-controlled, double-
blind study, comprising 47 healthy volunteers (aged 18–45 
years) who received dabigatran 220 mg bid for 3 days and 
a final dose on day 4, and then idarucizumab (1 g, 2 g, or 
4 g 5-min infusion, or 5 g plus 2.5 g in two 5-min infusions 
given 1 h apart) administered (each dose to 12 men) about 
2 hours after the final dabigatran dose, idarucizumab 
immediately and completely reversed dabigatran-induced 
anticoagulation in a dose-dependent manner.43 Drug-
related adverse events were all of mild intensity and 
reported in 7 participants (1 infusion site erythema and hot 
flushes, 2 epistaxis, 1 infusion site hematoma, and 3 
hematuria). No serious or severe adverse events were 
reported, no adverse event led to discontinuation of 
treatment, and no clinically relevant difference in 
incidence of adverse events was noted among the groups.   
Table 1. Antidotes for Non-Vitamin K Oral Anticoagulants  
Antidote Idarucizumab 
(Praxbind®) 
Andexanet 
alfa 
Aripazine, 
Ciraparantag 
(PER977) 
Manufactu 
rer 
Boehringer 
Ingelheim 
Portola Ph. Perosphere Inc. 
Type humanized 
monoclonal 
antibody 
fragment (Fab) 
Recombinant 
human Factor 
Xa variant (39 
kDa) 
small synthetic, 
cationic water-
soluble molecule 
(512 Da) 
NOAC Dabigatran Oral Factor 
Xa inhibitors 
All NOACs 
Cleared by Kidney ? ? 
Dose 5 g: 2 doses of 
2.5 g IV over 5-
10 min at 15 
min apart (2.5 
g/50 ml vial) 
400/800 mg 
followed by 
2-h infusion 
of 4-8 mg/min 
/ Lower doses 
for apixaban 
& higher for 
rivaroxaban 
100-300 mg IV 
Half-life 47 min (initial / 
10.3 h (terminal) 
1 h Onset of action: 10 
min / Duration of 
action: 24 h 
Studies REVERSE-AD ANNEXA-4 Phase 1 study 
 
A Phase 3 prospective cohort study, the RE-VERSE 
AD (A Study of the Reversal Effects of Idarucizumab on 
Active Dabigatran), was conducted to determine the safety 
of 5 g of IV idarucizumab and its capacity to reverse the 
anticoagulant effects of dabigatran in patients who had 
serious bleeding (group A) or required an urgent procedure 
(group B). According to an interim analysis of 90 patients 
who received idarucizumab (51 patients in group A and 39 
in group B),12 among 68 patients with an elevated dilute 
thrombin time test and 81 with an elevated ecarin clotting 
time at baseline, reversal was 100%. Idarucizumab 
normalized the test results within minutes in 88-98% of the 
patients. Concentrations of unbound dabigatran remained 
low (<20 ng/ml) at 24 h in 79% of the patients. Among 35 
assessed patients in group A, hemostasis was restored at a 
median of 11.4 hours. Among 36 patients in group B who 
underwent a procedure, normal intraoperative hemostasis 
was reported in 33, and mildly or moderately abnormal 
hemostasis in the other 3 patients. One thrombotic event 
occurred within 72 h after idarucizumab administration in 
a patient in whom anticoagulants had not been reinitiated.  
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Idarucizumab is available as a ready-to-use solution of 
50 mg/ml (two 2.5g/50-ml vials, kept in the refrigerator 
and having a 24-month shelf life) (see package insert: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/201
5/ 761025lbl.pdf). Before use, the unopened vials may be 
maintained at room temperature for up to 48 h if they are 
stored in the original package to protect them from light or 
for up to 6 h if exposed to light. A total IV dose of 5 g is 
administered as 2 consecutive 2.5-g infusions over 5-10 
min at <15 min apart, expected to reverse all of the 
available dabigatran (i.e., all unbound and protein-bound 
dabigatran and its active metabolites).41 Drug plasma 
concentrations decline in a biphasic manner with a rapid, 
initial half-life of ≈45 min with only 4% of the peak 
concentration remaining in plasma after 4 h. The drug is 
eliminated mainly renally. However, there should be no 
concern in patients with renal insufficiency, since these 
patients often have elevated dabigatran plasma 
concentrations, and thus the higher idarucizumab exposure 
may be advantageous. The drug normalizes dabigatran-
induced prolongation of the dTT (dilute thrombin time), 
ECT (ecarin clotting time), aPTT (activated partial 
thromboplastin time), TT (thrombin time), and activated 
clotting time within minutes in a dose-dependent manner. 
If the dTT or ecarin-based assays are not available, the 
aPTT or TT can be used to monitor dabigatran reversal 
with idarucizumab.  
The short half-life of idarucizumab in patients with 
normal renal function allows resumption of dabigatran 
therapy within 24 h in order to avoid the potential risk of 
thrombosis, provided that hemostasis has been secured.41  
The effect of idarucizumab is very rapid and sustained for 
12 h, meaning that surgery or other procedures can be 
started shortly after administration. A pre-procedural 
normal aPTT and TT confirms reversal of the 
anticoagulant effect. Post-procedurally and after adequate 
hemostasis is restored, in patients at high risk for bleeding, 
treatment can start with a low dose of an anticoagulant for 
thromboprophylaxis, and the dose can then be increased to 
a therapeutic level once the bleeding risk abates. Since 
idarucizumab is specific for dabigatran, the anticoagulant 
activity of other anticoagulants will not be affected. In 
patients with renal impairment, the half-life of 
idarucizumab is prolonged, hence reinitiation of 
dabigatran may need to be delayed or an alternative 
anticoagulant may need to be considered.  
Andexanet alfa is another antidote, in injectable form, 
recently developed by Portola Pharmaceuticals for factor 
Xa inhibitors. This recombinant protein is a modiﬁed form 
of factor Xa that is catalytically inactive but retains high-
afﬁnity binding to factor Xa inhibitors. In animal models, 
andexanet reversed immediately and in a dose-dependent 
manner the anticoagulant effect of factor Xa inhibitors, 
restored hemostasis and reduced bleeding.9, 44 In Phase 1 
and 2 studies in healthy volunteers, the antidote reversed 
antifactor Xa activity in a dose-dependent manner and no 
thrombotic events were reported.9 In these studies, it was 
observed that anticoagulation returned to pre-treatment 
levels within few hours after a bolus of the antidote and 
therefore a constant infusion of the drug is recommended 
to reverse anticoagulation for longer periods of time.  
More recently the combined results of ANNEXA-A 
and ANNEXA-R trials were reported.13 These trials 
evaluated the efficacy and safety of andexanet for the 
reversal of anticoagulation with apixaban or rivaroxaban 
in older healthy volunteers (mean age 58 years), who were 
given 5 mg of apixaban bid or 20 mg of rivaroxaban daily. 
Among the apixaban-treated individuals, anti–factor Xa 
activity was reduced by 94% among those who received an 
andexanet bolus (n=24), as compared with 21% among 
those who received placebo (n=9) (P<0.001), and unbound 
apixaban concentration was reduced by 9.3 ng/ml vs 1.9 
ng/ml (P<0.001); thrombin generation was fully restored 
in 100% vs 11% of the participants (P<0.001) within 2 to 
5 min. Among the rivaroxaban-treated individuals, anti–
factor Xa activity was reduced by 92% among those who 
received an andexanet bolus (n=27), as compared with 
18% among those who received placebo (n=14) (P<0.001), 
and unbound rivaroxaban concentration was reduced by 
23.4 ng/ml vs 4.2 ng/ml (P<0.001); thrombin generation 
was fully restored in 96% vs 7% of the participants 
(P<0.001). These effects were sustained when andexanet 
was administered as a bolus plus an infusion. No serious 
adverse or thrombotic events were reported. Another 
study, the ANNEXA-E (Andexanet Alfa a Novel Antidote 
to the Anticoagulant Effects of FXA Inhibitors-Edoxaban), 
is going to assess the effect of this antidote in patients 
receiving edoxaban. An ongoing trial (ANNEXA-4; 
NCT02329327) is evaluating the efficacy and safety of 
andexanet in patients (estimated to be enrolled: n=270) 
with factor Xa inhibitor–associated acute major bleeding 
(https://clinicaltrials.gov/ct2/show/NCT02329327).13  
Aripazine or ciraparantag or PER977, has been 
introduced as a universal antidote binding and inhibiting 
all NOACs;10, 11 however, it has so far only been studied in 
volunteers taking edoxaban and the mechanism of action 
remains unknown. Aripazine is a small, synthetic, water-
soluble, cationic molecule developed by Perosphere Inc. 
that binds to unfractionated heparin, low-molecular-
weight heparin, fondaparinux, dabigatran and to the new 
factor Xa inhibitors through hydrogen bonding and 
charge–charge interactions. Preliminary data are 
promising. The molecule effectively reverses bleeding 
associated with factor Xa inhibitors in animal models of 
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external and internal bleeding. In addition, the results of 
the ﬁrst human, Phase I study have been recently 
published. In this study, the effect of single IV doses of 
aripazine (5-300 mg) administered alone and after a 60-mg 
oral dose of edoxaban was examined in 80 healthy 
persons.45 After edoxaban, the mean whole-blood clotting 
time increased by 37% over the baseline value. In patients 
receiving a single IV dose of aripazine (100-300 mg) 3 
hours after the administration of edoxaban, the whole-
blood clotting time decreased to within 10% above the 
baseline value in <10 min, whereas in patients receiving 
placebo, this occurred much later (12-15 h). The whole-
blood clotting time remained within 10% above or below 
the baseline value for 24 h after the administration of a 
single dose of aripazine. Edoxaban anticoagulation 
significantly reduced the mean fibrin-fiber diameter 
(determined by scanning electron micrographs of clots) 
relative to baseline, which was restored to normal 30 min 
after administration of aripazine; there was no evidence of 
procoagulant activity after administration of aripazine 
(assessed by measuring levels of d-dimer, prothrombin 
fragment 1.2, and tissue factor pathway inhibitor and by 
whole-blood clotting time). Potentially related adverse 
events were transient mild perioral and facial flushing and 
dysgeusia; 1 person reported a moderate headache. In 
addition, 1 person had a moderate muscle cramp and 
elevation in creatinine kinase levels, events that were not 
considered to be related to aripazine. Thus, in this study, 
baseline hemostasis was restored from the anticoagulated 
state within 10-30 min after administration of 100-300 mg 
of aripazine and was sustained for 24 hours. Additional 
phase 2 clinical studies are ongoing.45   
Conclusion 
NOACs have been proven equivalent or superior to 
VKAs in the treatment of non-valvular AF and VTE, 
conferring protection from thromboembolic events with 
lessened occurrence of intracerebral hemorrhage. 
However, occurrence of major or life-threatening bleeding 
events is still quite possible; it has even been suggested that 
the rate of GI or other site major bleeding related to the use 
of at least some NOACs is higher than that reported in 
warfarin users. Thus, there is a major concern regarding 
the lack of a specific antidote and rapid reversal agent in 
case of a life-threatening bleeding event. The quicker 
dissipation of the anticoagulant effect of these agents due 
to their shorter half-life is not always entirely reassuring, 
particularly when urgent surgery with a high hemorrhagic 
risk is needed or in cases of intracerebral hemorrhage or 
serious bleeding in another critical organ, or even in cases 
of accidental overdose, where the anticoagulant effect 
should be promptly reversed. Fortunately, the 
development of effective specific NOAC antidotes has 
recently made great advances, with one having already 
gained FDA and EMA approval and another two agents 
already in the pipeline.   
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